|Principal Investigator/ Physician||Rodney Rocconi, MD|
|Cancer Site||Solid Tumor|
|Contact Email||MCI Clinical Trials|
Protocol Title: "Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphomas."
Inclusion Criteria: Patients must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma that has progressed following at least one line of standard systemic therapy. Patients must have tumor amenable to image guided or direct vision biopsy and be willing and able to undergo a tumor biopsy for molecular profiling; biopsy must not be considered to be more than minimal risk to the patient. Presence of one or more of the specific “actionable” mutations/amplifications of interest (see protocol).
Exclusion Criteria: Patients who require coumadin derivative anticoagulants, except low weight heparin for prophylactic use; uncontrolled illnesses including CHF, unstable angina, arrhythmia, cardiac metastases. Any prior radiotherapy or major surgery unless > 4 weeks prior to study treatment. Palliative radiation must be completed at least 2 weeks prior to study enrollment.
Clinical Trails.Gov Link: https://clinicaltrials.gov/ct2/show/NCT02465060?term=EAY131&rank=1
© 2018 USA Health System